UCB S.A.
Rating
Updated: Sep 18, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
A detailed description of the company is not yet available.
Latest News
5 days ago · zacks.com
UCB (UCBJY) Upgraded to Buy: Here's WhyUCB (UCBJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
23 days ago · zacks.com
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized DrugmakersTrump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
1 month ago · defenseworld.net
UCB (OTCMKTS:UCBJY) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell?Shares of UCB SA (OTCMKTS:UCBJY - Get Free Report) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $145.86 and traded as low as $122.54. UCB shares last traded at $122.60, with a volume of 26,717 shares. Analyst Ratings Changes A number of analysts have
2 months ago · seekingalpha.com
UCB SA (UCBJY) Q2 2026 Earnings Call TranscriptUCB SA (UCBJY) Q2 2026 Earnings Call Transcript
2 months ago · defenseworld.net
UCB SA (OTCMKTS:UCBJY) Short Interest Down 60.4% in JulyUCB SA (OTCMKTS:UCBJY - Get Free Report) was the target of a significant drop in short interest in the month of July. As of July 15th, there was short interest totaling 2,283 shares, a drop of 60.4% from the June 30th total of 5,769 shares. Currently, 0.0% of the company's stock are sold short. Based
Add to Watchlist
Select watchlists to add or remove UCBJY